Haloperidol vs Olanzapine for the Management of ICU Delirium

• Status: Terminated
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this randomized clinical trial is to determine whether haloperidol is superior to olanzapine for the treatment of ICU acquired delirium. The hypothesis is that haloperidol is in fact superior to olanzapine in treating ICU acquired delirium and sustaining delirium free time.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Richard Hall
• Collaborator: Dalhousie University
• Treatments: Haloperidol; Haloperidol decanoate; Methotrimeprazine; Olanzapine

Criteria

Inclusion Criteria:

• All patients who are 18 years or older who are admitted for more than 24 hours to the ICU.

• Patients screened for delirium using the ICDSC with a score greater than or equal to 4 or with clinical manifestations of delirium.

Exclusion Criteria:

• Patients unlikely to survive 24 hours.

• Patients with a primary neurologic reason (i.e. stroke, dementia-related psychosis) for ICU admission.

• Patients with QTc interval greater than 440 msec.

• Pregnant patients.

• Patients who are breast feeding.

• Patients in whom haloperidol, or olanzapine is contraindicated.

• Patients allergic to haloperidol, olanzapine, quetiapine, risperidone, loxapine or methotrimeprazine.

• Patients who do not have a urinary catheter.

• Patients who have received haloperidol, olanzapine, quetiapine, risperidone, loxapine or methotrimeprazine within 14 days.

• Patients unable to undergo assessment (i.e. patients with developmental disability or mental incapacity prior to ICU admission).

• Prolonged (greather than 24 hours) comatose patients who have a defined structural reason for their decreased level of consciousness.